Focal One® is a next-generation robotic platform that uses High-Intensity Focused Ultrasound (HIFU) to treat localized prostate cancer with extraordinary precision in a minimally invasive way. By concentrating ultrasound energy on specific areas of the prostate, it destroys cancerous tissue without damaging surrounding healthy structures.
The system combines real-time ultrasound imaging with pre-existing MRI or 3D biopsy data through its HIFUsion® software, enabling physicians to delineate and treat only the affected areas. Its robotic arm provides sub-millimetric accuracy, while safety mechanisms such as rectal wall cooling and real-time patient movement monitoring ensure a safe procedure.
Unlike traditional surgery or radiotherapy, Focal One® requires no incisions, results in minimal blood loss, and is often performed on an outpatient basis, allowing discharge on the same day in many cases. Clinical studies have shown that it provides oncological control comparable to radical prostatectomy, but with a significant reduction in the risks of urinary incontinence and erectile dysfunction. This translates into faster recovery and a better quality of life after treatment.
With its latest upgrade, Focal One® i, the system integrates AI-powered imaging tools, optimized workflows, and remote collaboration features, positioning it as one of the most advanced technologies available for focal treatment of prostate cancer.
Discover focal and non-invasive therapy: High-Intensity Focused Ultrasound (HIFU), an advanced option to treat prostate cancer without surgery.